Novo unveils new cardiometabolic data as it reports solid third-quarter profitsnews2024-11-06T12:05:48+00:00November 6th, 2024|Endpoints News|
‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugsnews2024-11-06T12:00:14+00:00November 6th, 2024|Endpoints News|
One biotech is looking to lessen antipsychotic-induced weight gain, despite new entrantsnews2024-11-05T19:48:52+00:00November 5th, 2024|Endpoints News|
#ASH24: Novo Nordisk takes Forma’s sickle cell treatment into Phase 3news2024-11-05T17:55:25+00:00November 5th, 2024|Endpoints News|
Zealand details Phase 1 obesity data for amylin drug as it plans next stepsnews2024-11-05T17:15:38+00:00November 5th, 2024|Endpoints News|
#ASH24: J&J’s Darzalex hits primary endpoint in Phase 3 early-stage multiple myeloma trialnews2024-11-05T17:14:17+00:00November 5th, 2024|Endpoints News|
#ASH24: Gilead and Arcellx spotlight safety of multiple myeloma cell therapy, dose first patient in Phase 3news2024-11-05T16:08:48+00:00November 5th, 2024|Endpoints News|
#ASH24: Sanofi reveals positive Phase 3 data for BTK inhibitor from $3.7B Principia takeovernews2024-11-05T15:57:22+00:00November 5th, 2024|Endpoints News|
#ASH24: Beam discloses first clinical data on base-edited sickle cell therapy, one patient deathnews2024-11-05T15:19:56+00:00November 5th, 2024|Endpoints News|
Sana narrows focus again to zero in on diabetes and autoimmune diseasenews2024-11-05T11:42:44+00:00November 5th, 2024|Endpoints News|
